Somatic PIK3CA and PTEN mutations with endothelial PI3K/AKT/mTOR activation in RAS-negative brain arteriovenous

Yukiko Hata1, Ryo Tanaka2, Shojiro Ichimata1

  • 1Department of Legal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.

Insights

Somatic PIK3CA mutations activate the PI3K pathway in brain arteriovenous malformations (bAVMs), suggesting a new molecular mechanism beyond RAS/MAPK signaling in these vascular lesions.

Area of Science:

  • Neurovascular diseases
  • Molecular genetics
  • Endothelial biology

Background:

  • Somatic mutations in endothelial signaling pathways are implicated in brain arteriovenous malformations (bAVMs).
  • RAS/MAPK pathway mutations are frequently identified, but other molecular drivers remain unclear.

Purpose of the Study:

  • To investigate alternative molecular mechanisms in bAVMs beyond RAS/MAPK pathway mutations.
  • To characterize the role of PIK3CA mutations and PI3K/AKT/mTOR pathway activation in bAVMs.

Main Methods:

  • Analysis of two autopsy-confirmed bAVMs with somatic PIK3CA mutations.
  • Histopathological examination and immunohistochemical analysis for pathway activation (PI3K/AKT/mTOR, ERK).
  • Targeted sequencing to identify mutations in RAS/MAPK and other relevant genes.

Main Results:

  • Both bAVMs harbored somatic PIK3CA mutations, with one also having a PTEN alteration.
  • Lesion-restricted activation of the PI3K/AKT/mTOR pathway was observed in endothelial cells.
  • Focal ERK phosphorylation and lack of pathogenic RAS/MAPK mutations suggested PI3K pathway dominance.
  • Variant allele frequencies were interpreted cautiously due to whole-genome amplification from autopsy tissue.

Conclusions:

  • PIK3CA-driven PI3K pathway activation represents a significant molecular mechanism in a subset of RAS-negative bAVMs.
  • These findings highlight the molecular heterogeneity of bAVMs.
  • Integrated genetic and pathological assessment is crucial for understanding bAVM pathogenesis.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...